{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:52:23Z","timestamp":1791298343653,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":678,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA78902"],"award-info":[{"award-number":["CA78902"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA018029"],"award-info":[{"award-number":["CA018029"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.bbmt.2013.03.001","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T03:15:23Z","timestamp":1363835723000},"page":"949-957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose"],"prefix":"10.1016","volume":"19","author":[{"given":"Merav","family":"Bar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chauncey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Storer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.D.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2013.03.001_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev.med.54.101601.152456","article-title":"The current status of hematopoietic cell transplantation","volume":"54","author":"Appelbaum","year":"2003","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bbmt.2013.03.001_bib2","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.03.001_bib3","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.03.001_bib4","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","article-title":"Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation","volume":"304","author":"Weiden","year":"1981","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.03.001_bib5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib6","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.03.001_bib8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2003-07-2344","article-title":"Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning","volume":"103","author":"Bethge","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbmt.2005.11.520","article-title":"Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions","volume":"12","author":"Huff","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/sj.bmt.1704807","article-title":"Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT)","volume":"35","author":"Michallet","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib11","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.03.001_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbmt.2007.04.013","article-title":"High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma","volume":"14","author":"Bloor","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.seminhematol.2005.09.005","article-title":"Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion","volume":"43","author":"Porter","year":"2006","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bbmt.2013.03.001_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V100.2.397","article-title":"Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose","volume":"100","author":"Guglielmi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib15","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib17","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bbmt.2011.01.004","article-title":"A\u00a0phase I\/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation","volume":"17","author":"Inamoto","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib18","first-page":"825","article-title":"1994 Consensus conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib20","first-page":"247","article-title":"Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry","volume":"4","author":"Atkinson","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/bmt.2009.177","article-title":"Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT","volume":"45","author":"Chalandon","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib22","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V91.10.3671","article-title":"Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant","volume":"91","author":"Alyea","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bmt.1704767","article-title":"Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning","volume":"35","author":"Flowers","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib24","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc1365","article-title":"Molecules and mechanisms of the graft-versus-leukaemia effect","volume":"4","author":"Bleakley","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bbmt.2013.03.001_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-642-56352-2_15","article-title":"Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas","volume":"159","author":"Liu","year":"2002","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.bbmt.2013.03.001_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.med.54.101601.152339","article-title":"Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant","volume":"54","author":"Vogelsang","year":"2003","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bbmt.2013.03.001_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","article-title":"Donor leukocyte infusions in acute lymphocytic leukemia","volume":"26","author":"Collins","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.03.001_bib30","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bmt.1702685","article-title":"Donor leukocyte infusions for multiple myeloma","volume":"26","author":"Salama","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib32","first-page":"1214","article-title":"Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions","volume":"95","author":"Porter","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.bmt.1701224","article-title":"Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors","volume":"21","author":"van Rhee","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.03.001_bib34","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.03.001_bib35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","article-title":"Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited","volume":"36","author":"Deol","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bbmt.2013.03.001_bib36","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/sj.leu.2403523","article-title":"Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse","volume":"18","author":"Choi","year":"2004","journal-title":"Leukemia"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113001055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113001055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:44:35Z","timestamp":1761057875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879113001055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1083879113001055"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.03.001","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}